Amgen and Roche target Samsung’s Bioepis in patent suit
01-05-2019
clu / iStockphoto.com
Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board (PTAB) decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors (IL-4R).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Immunex, Sanofi-Aventis, Sanofi, Regeneron, PTAB, US Court of Appeals for the Federal Circuit, biologic, Dupixent, patent invalidation
